Retrofitted CAR-T failures are frequent

News events these two days modified CAR-T enterprise Unum and Bellicum have issued adverse news.
BLCM announced a 79% cut yesterday and will focus on developing bpX-601s targeting PSCA and BPX-603 targeting HER2.
BPX-601 only produces some stable diseases in solid tumors without any response, while BPX-603 is just beginning to be clinical and faces a variety of new HER2 therapies.
unum today announced a name for Cogent and called in a new CEO.
also cut 60 per cent of its staff in March, abandoning ACTR707 and 087, which are already clinical, to focus on preclinical.
car-T pioneers are now small micro-enterprises with a market capitalisation of less than $100 million.
Drug Source Analysis CAR-T is an important breakthrough in late-stage oncology therapy in recent years, Emma Whitehead's inspirational story spread across the river north and south, Kite and Juno have been bought by big drug companies for 10 billion prices, famous investors are reviewing why they missed such a big fish that year.
but CAR-T therapy is currently limited to blood tumors and faces a squeeze from easier-to-use, simpler ADC and dual-anti-drugs.
Because car-T production is time-consuming and patients with end-line drugs sometimes fail to provide T-cells in a timely manner, the efficacy of the treatment may be exaggerated based on response rates alone, as many serious patients have died before medication or evaluation.
although patients who use these therapies have a high response rate, some CAR-T response times are no longer than those of ADC, and the survival advantage is much higher than that of controlled trials.
of course the biggest problem is the small number of solid tumor-specific antigens and the toxicity of cytokine storms.
Unum's technology platform, Antibody-Tumor Cell Killing, uses existing tumor antibody drugs as an alternative targeting tool, theoretically using a universal head to transport different cargoes and target tumor cells that express different tumor antigens as needed.
company's Latin motto "E pluribus unum" from the U.S. national emblem, Chinese was translated as "one for all", a bit of a unifying meaning.
this platform may produce CAR-T that targets multiple antigens more efficiently, it does not solve the more core problems of antigen specificity, solid tumor immunosuppression environment, etc.
more patients died after unum products entered the clinic than cured patients, and clinical trials were called off several times.
the core purpose of BLCM technology is to make CAR-T more controllable, mainly by starting or braking CAR-T with chemicals.
techniques, such as CaspaCIDe® introduce the gene technology of the supply T cells into a suicide mechanism, adding a protein apoptosis enzyme.
the enzyme is then connected to a binding region with a compound called rimiducid, which in combination with rimiducid activates the cystic protease, which initiates a apoptosis procedure to kill the T cell.
this mechanism can also be used to control the activation of CAR-T cells.
but the earliest product BPX-501 did not show much safety benefits, causing multiple brain injuries in clinical trials.
now the product line of the two products are not high degree of control, to fight a few fires to start, in pancreatic cancer did not produce any response.
there are some questions about the patent for this technology, and BLCM is in a much awkward position compared to Kite and Juno, who started out at the same time.
CAR-T is undoubtedly one of the most cutting-edge medical technologies today, kite and Juno are very successful pioneers.
regrets that being one step closer to the forerunner in the field of new drugs is usually not the forerunner, but the forerunner.
is not clear how many mature products have succeeded, let alone the most cutting-edge technologies.
the success of Kymriah and Yescarta isn't all car-T's workings, but the little devils who haven't been seen yet don't happen to be messing around with the two drugs on the market.
even these listed drugs have gone through nine deaths, and there have been patient deaths and clinical suspensions.
CAR-T may be the most rationally designed drug in pharmaceutical history, but even so, advances in technology rely more on the stupid method of trial and error, a strategy that relies on high-quality, diverse candidate technologies from explorers such as Unum and BLCM.
is inevitable, but it is also necessary.